Compassionate Certification Centers will launch the first Irritable Bowel Syndrome clinical research study in partnership with Affinity Bio Partners, SciCann Therapeutics, and FSD Pharma.
PITTSBURGH, Nov. 8, 2018 /PRNewswire-PRWeb/ — Compassionate Certification Centers™, a medical cannabis healthcare network, in partnership with Affinity Bio Partners, was recently selected by SciCann Therapeutics and FSD Pharma to launch the first clinical research study on Irritable Bowel Syndrome (IBS) in Pittsburgh, Pennsylvania.
Established in 2017, Compassionate Certification Centers is known for its educational events and outreach. Co-founder and Chief Medical Officer Dr. Bryan Doner will lead the IBS study alongside Christina DiArcangelo Puller, CEO of Affinity Bio Partners, a clinical research organization.
“We are excited to have been selected as the Clinical Research Organization for SciCann Therapeutics’ IBS study and look forward to advancing medical cannabis education and research with Affinity Bio Partners,” stated Doner.
The pioneering clinical research study will potentially aid in furthering the therapeutic benefits of the cannabis plant. Affinity Bio Partners and Compassionate Certification Centers will utilize cutting-edge technology during the study, including the CannaBot™ an artificial intelligence bot from AI Health Outcomes.
Compassionate Certification Centers provides CBD and medical cannabis evaluations and certifications at its eight offices across Western Pennsylvania. The progressive healthcare network recently launched its own line of THC-free CBD products, available to patients and non-cardholders.
In 2019, Compassionate Certification Centers will host its 3rd Annual World Medical Cannabis Conference & Expo. For more information visit cccregister.com.
About Compassionate Certification Centers
Compassionate Certification Centers provides professional, compassionate, and private evaluations for patients seeking to legally obtain a Pennsylvania medical marijuana card, as well as the retail of compliant CBD products made in the United States. The company’s medical marijuana certification centers are located in the following counties: Allegheny, Armstrong, Butler, Cumberland County, Clarion, Dauphin, Erie, Westmoreland, Washington, Greene, Philadelphia, Lackawanna, West Chester.
Compassionate Certification Centers’ mission is to raise the level of treatment that patients receive while seeking their medical marijuana cards by providing trust, clarity, and the diagnostic help from certified doctors. Compassionate Certification Centers is here to improve the lives of people suffering from chronic health conditions by helping them to find the right medicine. For information, visit compassionatecertificationcenters.com or join the discussion at Facebook, Twitter, LinkedIn, Instagram and Google+.
About Affinity Bio Partners
Affinity Bio Partners is a Clinical Research Organization (CRO) that provides best in class services while maintaining a personal approach. There are many CROs in the market, but there is only one that will give our client’s organization the attention, services and results. For more information on the company or general inquiries, please email: info@affinitybiopartners.com or visit us at http://www.affinitybiopartners.com. Follow us on twitter at AffinityBioP, Facebook, LinkedIn and Instagram.
About FSD Pharma
FSD Pharma is focused on the development of the highest quality indoor grown, pharmaceutical grade cannabis and on the research and development of novel cannabinoid-based treatments for several central nervous system disorders, including chronic pain, fibromyalgia and irritable bowel syndrome. The Company’s phase one growth plan involves the development of 25,000 square feet of indoor grow space at its Ontario facility and an additional 220,000 square feet, which pending approval by Health Canada, is expected to be operational in the first quarter 2019. FSD facilities sit on 72 acres of land with 40 acres primed for development and an expansion capability of up to 3,896,000 square feet.
FSD’s wholly-owned subsidiary, FV Pharma, is a licensed producer of cannabis having received its cultivation license under the Access to Cannabis for Medical Purposes Regulations (ACMPR) on October 13, 2017 and is now operating under the recently enacted Cannabis Act. FV Pharma vision is to transform its current headquarters in a Kraft plant in Cobourg, Ontario into the largest hydroponic indoor grow facility in the world. FV Pharma intends to cover all aspects of this exciting, new industry, including cultivation, legal, processing, manufacturing, extracts and research and development.
